US EditionPlexision Secures Investment to Accelerate AI in Transplant Diagnostics
Summary by hitconsultant.net
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Plexision Secures Investment to Accelerate AI in Transplant Diagnostics
What You Should Know: – Plexision, a biotechnology company, today announced a $365k investment from the Richard King Mellon Foundation. The funds will be used to accelerate the integration of artificial intelligence (AI) and machine learning (ML) capabilities across Plexision’s suite of cell-based blood tests, significantly improving predictive accuracy for complex transplant outcomes. Despite advances in transplant medicine, managing immunosup…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
